Similar Search Results

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677

Private and Social Returns to R&D : Drug Development and Demographics

Benmelech, Efraim; Eberly, Janice C.; Krieger, Joshua L.; … - National Bureau of Economic Research - 2021

Investment in intangible capital--in particular, research and development--increased dramatically since the 1990s. However, productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer...

Persistent link: https://www.econbiz.de/10012482573

Investigator Racial Diversity and Clinical Trial Participation

Alsan, Marcella; Campbell, Romaine A.; Leister, Lukas; … - National Bureau of Economic Research - 2023

We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...

Persistent link: https://www.econbiz.de/10014372489

Price Indices and the Value of Innovation with Heterogenous Patients

Lucarelli, Claudio; Nicholson, Sean; Tilipman, Nicholas - National Bureau of Economic Research - 2021

justify high prices for the population as a whole, innovation improves the welfare of sicker, late-stage cancer patients. A …

Persistent link: https://www.econbiz.de/10012482551

Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions

Garthwaite, Craig; Sachs, Rebecca; Stern, Ariel D. - National Bureau of Economic Research - 2021

Pharmaceutical innovation policy involves managing a tradeoff between high prices for new products in the short … pharmaceuticals, suggesting low(er) price markets may have different dynamics with respect to innovation policy …

Persistent link: https://www.econbiz.de/10012533304

Improving Regulation for Innovation : Evidence from China's Pharmaceutical Industry

Jia, Ruixue; Ma, Xiao; Yang, Jianan; Zhang, Yiran - National Bureau of Economic Research - 2023

This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …

Persistent link: https://www.econbiz.de/10014447297

Fertility and Labor Market Responses to Reductions in Mortality

Bhalotra, Sonia R.; Venkataramani, Atheendar S.; … - National Bureau of Economic Research - 2022

We investigate women's fertility, labor and marriage market responses to a health innovation that led to reductions in …

Persistent link: https://www.econbiz.de/10013361971

Regulatory Incentives for Innovation : The FDA's Breakthrough Therapy Designation

Chandra, Amitabh; Kao, Jennifer L.; Miller, Kathleen L.; … - National Bureau of Economic Research - 2022

clinical trial design complexity. The results suggest that targeted regulatory innovation can shorten R&D periods without …

Persistent link: https://www.econbiz.de/10013477204

The Feasibility of Using Bayh-Dole March-In Rights to Lower Drug Prices : An Update

Ouellette, Lisa Larrimore; Sampat, Bhaven N. - National Bureau of Economic Research - 2024

In December 2023, the Biden-Harris Administration released a proposed framework for exercising government "march-in" rights on high-priced taxpayer-funded drugs. While both proponents and critics of the new rules view them as having broad scope, march-in rights can be exercised only on patents...

Persistent link: https://www.econbiz.de/10014512071

Evaluation and Learning in R&D Investment

Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023

We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...

Persistent link: https://www.econbiz.de/10014287391